Novel Immunotherapeutics for Inflammatory Injury, Fibrosis and Vascular Leak
Uncontrolled inflammation and vascular leakage are at the core of life-threatening disease, but effective treatments remain limited.
At Aqualung Therapeutics, we are developing targeted therapies to interrupt these processes at their source, with the potential to redefine treatment and improve outcomes for patients worldwide.
Our Pipeline
We focus on developing novel therapies for diseases with significant unmet need, using distinct, science-driven approaches grounded in our core discoveries.
Latest Aqualung Therapeutics News
Aqualung Therapeutics Presents at the 2026 Gator Pitch presented by the University of Florida
March 5, 2026
Randomized Phase 2a PUERTA trial: ALT-100 mAb reduced organ injury vs placebo in ARDS, with no drug-related serious adverse events. Published in the American Journal of Respiratory and Critical Care Medicine
July 2026
Aqualung Therapeutics Receives FDA Clearance for Phase 2a Lung Fibrosis Study
December 5, 2025
Aqualung Therapeutics Receives NIH STTR Grant Award $1.2M to develop ALT-100 mAb for Progressive Pulmonary Fibrosis
September 15, 2025